Diabetic Neuropathy Treatment Market Set To Grow From USD 4.71 Billion In 2024 To USD 9.93 Billion By 2034

2026-02-04 09:17:07

(MENAFN- GlobeNewsWire - Nasdaq) The global diabetic neuropathy treatment market size was valued at USD 5.07 billion in 2025 and is predicted to hit around USD 9.93 billion by 2034, rising at a 7.75% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

Ottawa, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The global diabetic neuropathy treatment market

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @

Key Takeaways

North America accounted for the largest share of the diabetic neuropathy treatment market in 2024.
Asia Pacific is expected to grow at the fastest CAGR in the studied years.
By disorder type, the peripheral neuropathy segment registered dominance in the market in 2024.
By disorder type, the autonomic neuropathy segment is expected to grow at a notable CAGR in the market during the forecast period.
By drug class type, the non-steroidal anti-inflammatory drugs (NSAIDs) segment led the market in 2024.
By drug class type, the opioid segment is expected to grow at a significant rate in the market during the forecast period.
By distribution channel type, the hospital pharmacies segment dominated the market.
By distribution channel type, the online segment is predicted to grow at a significant rate in the market during the forecast period.

What is Diabetic Neuropathy Treatment?

Medical and lifestyle interventions aimed at managing nerve damage caused by diabetes, reducing pain, improving nerve function, and preventing complications through glucose control, medications, and supportive therapies. The diabetic neuropathy treatment market is growing due to the rising global prevalence of diabetes, which increases the risk of nerve damage. Growing awareness of diabetes-related complications, advancements in pain management therapies, and the development of innovative drugs and combination treatments are driving the damage. Additionally, increasing access, aging populations, and lifestyle-related risk factors are further fueling the expansion of treatments for diabetic neuropathy worldwide.

What are the Key Drivers in the Diabetic Neuropathy Treatment Market?

Rising global diabetes prevalence, growing awareness of neuropathic complications, and increasing demand for effective pain management are primary drivers

For Instance,

In April 2025, NeuroProTM launched an upgraded foot massager that helps relieve diabetic neuropathy pain, burning, and tingling with just 15 minutes of daily use.

You can place an order or ask any questions, please feel free to contact us at ...

What are the Ongoing Trends in the Diabetic Neuropathy Treatment Market?

In March 2025, Lexicon Pharmaceuticals reported encouraging Phase 2b trial outcomes for pilavapadin (LX9211), an oral, non-opioid AAK1 inhibitor. The investigational therapy demonstrated potential benefits in adults suffering from moderate to severe diabetic peripheral neuropathic pain.
In October 2024, Lyka Labs received CDSCO approval to manufacture and commercialize Pregabalin Gel 8% w/w for managing diabetic neuropathy pain. The topical formulation is intended to relieve nerve-related pain caused by diabetic nerve damage, offering a targeted treatment option for affected patients.

What is the Emerging Challenge in the Diabetic Neuropathy Treatment Market?

The diabetic neuropathy treatment market faces challenges such as limited disease-modifying therapies, variable patient response to pain medications, side-effect concerns, high treatment costs, and difficulties in early diagnosis, which hinder optimal disease management and long-term patient outcomes.

Regional Analysis

What Made North America Dominant in the Diabetic Neuropathy Treatment Market in 2024?

North America dominated the market in 2024 due to the high prevalence of diabetes, strong awareness of neuropathic complications, and early diagnosis rates. The region benefits from advanced healthcare infrastructure, rapid adoption of innovative therapies, and significant R&D investments. Favorable reimbursement policies, strong presence of leading pharmaceutical companies

How did the Asia Pacific Expand At the Fastest Pace in the Market in 2024?

Asia Pacific expanded at the fastest pace in the neuropathy treatment market in 2024 due to the rapidly rising diabetic population, increasing healthcare awareness, and improving access to diagnosis and treatment. Growth in healthcare infrastructure, expanding pharmaceutical manufacturing, and greater availability of affordable therapies supported adoption. Additionally, supportive government initiatives, rising healthcare spending, and growing acceptance of advanced and alternative treatment options across emerging economies accelerated regional market expansion.

Become a valued research partner with us -

Segmental Insights

By Disorder Type Analysis

How did the Peripheral Neuropathy Segment Dominate the Diabetic Neuropathy Treatment Market in 2024?

The peripheral neuropathy segment dominated the diabetic neuropathy treatment market in 2024 because it is the most common and clinically significant form of diabetic nerve damage. High prevalence among long-term patients, frequent symptoms such as pain, numbness, and tingling, and the need for continuous pain management drove demand. Wide availability of approved drug therapies, topical treatments, and medical devices further supported the segment's leading market share

The autonomic neuropathy segment is expected to grow at a notable CAGR during the forecast period due to increasing recognition of diabetes-related autonomic complications affecting cardiovascular, gastrointestinal, and urogenital functions. Improved diagnostic capabilities, rising clinical awareness, and growing focus on comprehensive diabetes management are driving demand. Additionally, ongoing research, development of targeted therapies

By Drug Class Type Analysis

Why Non-steroidal Anti-inflammatory Drugs (NSAIDs) Segment Dominated the Diabetic Neuropathy Treatment Market?

The non-steroidal anti-inflammatory drugs (NSAIDs) segment dominated the market due to their widespread use for managing mild to moderate neuropathic pain and inflammation. Easy availability, affordability, and rapid pain-relief effects made NSAIDs a common first-line option, especially in early disease stages. Their broad physician familiarity, over-the-counter accessibility in many regions, and use alongside other therapies further supported high adoption across diverse patient populations.

The opioid segment is expected to grow at a significant CAGR during the forecast period due to increasing use in managing severe and treatment-resistant diabetic neuropathic pain. For patients unresponsive to conventional therapies, opioids provide effective pain control and improved quality of life. Growing clinical acceptance for short-term and controlled use, availability of newer formulations with improved safety profiles, and rising cases of advanced neuropathy are further supporting segment growth.

By Distribution Channel Type

How did the Hospital Pharmacies Segment Dominate the Market in 2024?

The hospital pharmacies segment dominated the diabetic neuropathy treatment in 2024 due to the high rate of hospital visits for diagnosis, pain management, and treatment of diabetes-related complications. Availability of prescription-based therapies, specialized supervision, and access to advanced medications supported higher dispensing through hospitals. Additionally, integrated care settings, better reimbursement coverage, and trust in hospital-based treatment channels reinforced the segment's leading market share.

The online segment is expected to grow at a significant rate due to increasing rate due to increasing digital health adoption

Get the latest insights on life science industry segmentation with our Annual Membership:

What are the Recent Developments in the Diabetic Neuropathy Treatment Market?

In November 2024, Eva Pharma expanded into Nigeria by launching a portfolio of diabetes-related therapies aimed at improving access to affordable, high-quality care. The lineup includes Gliptus Plus for blood sugar control, Thiotacid for diabetic neuropathy management, and Donifoxate for hyperuricemia and gout, unveiled during a product launch event held in Lagos.
In January 2024, Neuralace Medical received U.S. FDA clearance for its Axon Therapy device, designed to manage chronic painful diabetic neuropathy. The non-invasive neuromodulation technology provides an alternative option for patients seeking drug-free relief from diabetes-related nerve pain.

Diabetic Neuropathy Treatment Market Key Players List

Pfizer. Inc
Abbott
Janssen Pharmaceuticals, Inc
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd
Lupin Pharmaceuticals
Novartis
Astellas Pharma Inc
Boehringer Ingelheim GmbH

Browse More Insights of Towards Healthcare:

The global cervical cancer treatment market

The global acne treatment market

The global mental health treatment market

The global brain tumor treatment market

The global sleeping bruxism treatment market

The hair treatment drug market

The huntington's disease treatment market

The global hematuria treatment market

The global food allergy treatment market

The fibromyalgia treatment market

Segments Covered in the Report

By Disorder Type

Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

By Drug Class

Capsaicin
Opioid

Morphine
Others

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

Ibuprofen
Naproxen
Others

Antidepressants

Tricyclic Antidepressants (TCAs)

Amitriptyline
Imipramine
Others

Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)

Duloxetine
Others

Selective Serotonin Reuptake Inhibitors (SSRIs)

Citalopram
Paroxetine
Others

Anticonvulsant Drugs

Gabapentin
Pregabalin
Topiramate
Others

Other

By Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Other

By Region

North America

U.S.
Canada

Europe

UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway

Asia Pacific

Japan
China
India
South Korea
Australia
Thailand

Latin America

Brazil
Mexico
Argentina

Middle East & Africa

South Africa
Saudi Arabia
UAE
Kuwait

Immediate Delivery Available | Buy This Premium Research @

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard:

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research

You can place an order or ask any questions, please feel free to contact us at ...

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web:

Our Trusted Data Partners

Precedence Research | Towards Packaging | Towards Food and Beverages | Towards Chemical and Materials | Towards Dental | Towards EV Solutions | Healthcare Webwire

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Also Read:

/insights/surgical-microscopes-market-sizing

/insights/iv-bags-market-sizing

/insights/multiple-sclerosis-diagnosis-and-treatment-market-sizing

/insights/atrial-fibrillation-treatment-market-sizing

/insights/cutaneous-squamous-cell-carcinoma-treatment-market-sizing

/insights/tendonitis-treatment-market-sizing

/insights/diabetic-neuropathy-treatment-market-sizing

/insights/oral-diabetes-medicine-market-sizing

/insights/spinal-cord-injury-treatment-market-sizing

/insights/infertility-treatment-market-sizing

MENAFN04022026004107003653ID1110695245

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.